New immunotherapy shows encouraging results for stiff person syndrome patients
Patients in a US trial using CAR-T cell therapy have regained ability to walk and return to work, according to Mayo Clinic doctors.

Neurologists in the US trialling a novel form of immunotherapy have reported exciting and very encouraging results for people living with stiff person syndrome (SPS). The treatment, known as CAR-T cell therapy, has prompted dramatic improvements in patients.
During the study, SPS patients' own T cells were extracted and engineered to wipe out disease-causing cells. This therapy, which is already used to treat cancer, reprograms a patient's immune cells to help fight disease.
Patients who previously struggled to walk and needed help with basic daily tasks have regained their ability to take part in everyday life. Some patients have even returned to work and resumed hobbies.
Jonathan Walden, a patient in the trial, had reached a point where walking and basic daily tasks required help from his family. After receiving CAR-T, he has returned to work and can go hunting and fishing.
Shari St Germain, another patient, experienced severe leg cramps, difficulty walking, muscle rigidity, and falls. Following the treatment, she reported that every day feels better and better, noting she was able to walk on a treadmill for seven minutes.
Dr Anastasia Zekeridou, a neurologist and researcher at Mayo Clinic in Rochester, said the degree of improvement seen in some patients was striking. Dr Sean Pittock, chair of the department of neurology at Mayo Clinic, said the results offer tremendous hope for people living with SPS and potentially other immune-mediated neurologic conditions.
Key facts
- CAR-T cell therapy has shown dramatic improvements in patients with stiff person syndrome.
- Patients in the trial have regained the ability to walk and return to work.
- Stiff person syndrome is a rare disease that attacks the central nervous system.
Three perspectives
Neutral
Neurologists in the US are trialling CAR-T cell therapy to treat stiff person syndrome, a rare disease that attacks the central nervous system.
Positive
The novel immunotherapy has prompted dramatic improvements, allowing some patients to return to work and resume hobbies.
Negative
Despite decades of research, there is no cure for stiff person syndrome.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.